Experienced in Thymic Epithelial Tumor

Dr. Filip J. Janku

Internal Medicine

1515 Holcombe Blvd,

Houston, TX

Clinical Trials:Currently Recruiting for 1 Trial

Experienced in Thymic Epithelial Tumor

1515 Holcombe Blvd,

Houston, TX

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Filip Janku is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Janku is rated as an Experienced provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Gastrointestinal Stromal Tumor, Colorectal Cancer, Lung Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Tissue Biopsy.

His clinical research consists of co-authoring 284 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Thymic Epithelial Tumor.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

1515 Holcombe Blvd, Houston, TX 77030

Call: 713-792-6161

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

Enrollment Status: Recruiting

Publish Date: August 15, 2025

Intervention Type: Drug

Study Drugs: BCA101, Pembrolizumab

Study Phase: Phase 1

A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: October 14, 2025

Intervention Type: Drug, Biological

Study Drugs: Pembrolizumab, Clostridium Novyi-NT, Doxycycline

Study Phase: Phase 1

A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations

Enrollment Status: Terminated

Publish Date: September 16, 2025

Intervention Type: Drug

Study Drug: HMPL-306

Study Phase: Phase 1

A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations

Enrollment Status: Suspended

Publish Date: September 03, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: July 03, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers

Enrollment Status: Terminated

Publish Date: May 16, 2025

Intervention Type: Drug, Biological

Study Phase: Phase 2

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: April 09, 2025

Intervention Type: Drug

Study Drug: ASTX295

Study Phase: Phase 1

A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: February 19, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Enrollment Status: Terminated

Publish Date: January 13, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Enrollment Status: Terminated

Publish Date: June 04, 2024

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab

Enrollment Status: Terminated

Publish Date: May 03, 2024

Intervention Type: Drug

Study Drugs: SYNB1891, Atezolizumab

Study Phase: Phase 1

A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab

Enrollment Status: Unknown

Publish Date: November 09, 2023

Intervention Type: Combination product

Study Phase: Phase 2

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Enrollment Status: Completed

Publish Date: April 14, 2023

Intervention Type: Drug, Biological

Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab

Study Phase: Phase 1

A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations

Enrollment Status: Terminated

Publish Date: December 21, 2022

Intervention Type: Drug

Study Phase: Phase 1

An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies

Enrollment Status: Completed

Publish Date: June 22, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas

Enrollment Status: Completed

Publish Date: April 13, 2022

Intervention Type: Drug

Study Drug: FF-10502-01

Study Phase: Phase 1/Phase 2

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Enrollment Status: Completed

Publish Date: October 12, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Study Exploring the Use of the Foundation Medicine Genomic Profiling Assay in a Phase I Solid Tumor Patient Population

Enrollment Status: Completed

Publish Date: June 14, 2021

Intervention Type: Procedure

A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease

Enrollment Status: Withdrawn

Publish Date: March 17, 2021

Intervention Type: Other, Drug

Study Phase: Phase 2

A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: March 04, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: February 25, 2021

Intervention Type: Biological, Drug

Study Phase: Phase 1

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Enrollment Status: Completed

Publish Date: February 18, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: January 22, 2021

Intervention Type: Other, Drug

Study Phase: Phase 1

A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: December 21, 2020

Intervention Type: Drug

Study Phase: Phase 1

Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance

Enrollment Status: Completed

Publish Date: December 19, 2020

Intervention Type: Drug, Biological, Other

Study Phase: Phase 1

A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: July 09, 2020

Intervention Type: Drug

Study Phase: Phase 1

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: March 20, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Enrollment Status: Terminated

Publish Date: September 19, 2019

Intervention Type: Drug

Study Phase: Phase 1

Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies

Enrollment Status: Completed

Publish Date: September 09, 2019

Intervention Type: Biological

Study Phase: Phase 1

View 28 Less Clinical Trials

284 Total Publications

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

Journal: JCO precision oncology

Published: August 27, 2025

View All 284 Publications

Similar Doctors

Experienced in Thymic Epithelial Tumor

Dr. Carl M. Gay

Internal Medicine

Experienced in Thymic Epithelial Tumor

Dr. Carl M. Gay

Internal Medicine

MD Anderson

1515 Holcombe Blvd,

Houston, TX

(0.1 miles away)

713-794-5446

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Carl Gay is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Gay is rated as a Distinguished provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and ALK-Positive Non-Small Cell Lung Cancer.

Experienced in Thymic Epithelial Tumor

Dr. Basti J. Thampoe

Internal Medicine

Experienced in Thymic Epithelial Tumor

Dr. Basti J. Thampoe

Internal Medicine

Makarios Hospitalist Group PLLC

21238 Kingsland Blvd,

Katy, TX

(21.2 miles away)

713-464-7555

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Basti Thampoe is a primary care provider, practicing in Internal Medicine in Katy, Texas. Dr. Thampoe is rated as an Advanced provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), End-Stage Renal Disease (ESRD), Bladder Reconstruction, and Ureteroscopy. Dr. Thampoe is currently accepting new patients.

Experienced in Thymic Epithelial Tumor

Dr. Saumil S. Datar

Internal Medicine | General Practice

Experienced in Thymic Epithelial Tumor

Dr. Saumil S. Datar

Internal Medicine | General Practice

1515 Holcombe Blvd,

Houston, TX

(0.1 miles away)

713-792-6161

Languages Spoken:

English

See accepted insurances

Saumil Datar is a primary care provider, practicing in Internal Medicine and General Practice in Houston, Texas. Dr. Datar is rated as an Experienced provider by MediFind in the treatment of Thymic Epithelial Tumor. His top areas of expertise are SVC Obstruction, Common Variable Immune Deficiency, Cushing's syndrome, and Teratoma of the Mediastinum.

VIEW MORE THYMIC EPITHELIAL TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Janku's expertise for a condition

ConditionClose